MA49250A - Nouveaux anticorps anti-cd3 - Google Patents

Nouveaux anticorps anti-cd3

Info

Publication number: MA49250A
Authority: MA; Morocco
Prior art keywords: antibodies; new anti; new
Prior art date: 2017-06-05

Application number

MA049250A

Other languages

English (en)

Inventor

Teddy Beltrametti

Tea Gunde

Christian Hess

Sebastian Meyer

Alexandre Simonin

David Urech

Original Assignee

Numab Therapeutics AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-05

Filing date

2018-06-04

Publication date

2021-04-14

2018-06-04 Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG

2021-04-14 Publication of MA49250A publication Critical patent/MA49250A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

MA049250A 2017-06-05 2018-06-04 Nouveaux anticorps anti-cd3 MA49250A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762515293P	2017-06-05	2017-06-05
EP17203832		2017-11-27

Publications (1)

Publication Number	Publication Date
MA49250A true MA49250A (fr)	2021-04-14

Family

ID=62555064

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA049250A MA49250A (fr)	2017-06-05	2018-06-04	Nouveaux anticorps anti-cd3

Country Status (10)

Country	Link
US (2)	US11319371B2 (fr)
EP (2)	EP3634998B8 (fr)
JP (1)	JP7247110B2 (fr)
KR (1)	KR102651965B1 (fr)
CN (1)	CN110691789A (fr)
AU (2)	AU2018280681B2 (fr)
CA (1)	CA3064163A1 (fr)
ES (1)	ES3015105T3 (fr)
IL (1)	IL271128B2 (fr)
MA (1)	MA49250A (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3634998B8 (fr) *	2017-06-05	2025-04-09	Numab Therapeutics AG	Anticorps anti cd3 epsilon
SG11201911527QA (en) *	2017-06-05	2020-01-30	Numab Therapeutics AG	Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
CN114276451B (zh) *	2020-09-27	2025-07-01	嘉和生物药业有限公司	靶向CD3e/g的抗体或其抗原结合片段、其制备和应用
KR20240109605A (ko) *	2021-09-13	2024-07-11	산둥심시어 바이오파마슈티칼 씨오., 엘티디.	항-인간 cd3 항체 및 이의 응용
EP4416182A4 (fr) *	2021-10-12	2025-09-17	Lepu Biopharma Co Ltd	Anticorps anti-cd3 avec réactivité croisée vis-à-vis des protéines humaines et de cynomolgus
US20250223358A1 (en) *	2022-03-09	2025-07-10	Antengene Biologics Limited	Novel anti-cd3 antibodies and uses thereof
CN115286715B (zh) *	2022-05-18	2023-05-23	上海百英生物科技股份有限公司	一种抗cd3的纳米抗体或其抗原结合部分及其制备方法
CN116284391B (zh) *	2022-11-16	2023-08-08	艾可泰科(浙江)控股有限公司	使用胰岛干细胞和抗体治疗糖尿病
WO2024155805A2 (fr) *	2023-01-19	2024-07-25	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Anticorps monoclonaux etv1
EP4688832A1 (fr) *	2023-03-29	2026-02-11	Nanjing GenScript Biotech Co., Ltd.	Anticorps et variants de ceux-ci contre le groupe humain de la protéine de différenciation 3

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
EP0571613B1 (fr)	1991-12-13	2003-09-17	Xoma Corporation	Materiels et methodes pour preparer des domaines variables d'anticorps modifies et leurs utilisations therapeutiques
EP1958962A3 (fr)	1997-06-12	2013-05-01	Novartis International Pharmaceutical Ltd.	Polypeptides anticorps artificiels
US7112324B1 (en)	1998-04-21	2006-09-26	Micromet Ag	CD 19×CD3 specific polypeptides and uses thereof
DE19819846B4 (de)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalente Antikörper-Konstrukte
EP1940881B1 (fr)	2005-10-11	2016-11-30	Amgen Research (Munich) GmbH	Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
RU2769948C2 (ru)	2007-04-03	2022-04-11	Эмджен Рисерч (Мьюник) Гмбх	CD3-Эпсилон-связывающий домен с межвидовой специфичностью
RS53008B2 (sr)	2007-04-03	2022-12-30	Amgen Res Munich Gmbh	Interspecijski specifičan cd3-epsilon vezujući domen
EP2370467B1 (fr) *	2008-10-01	2016-09-07	Amgen Research (Munich) GmbH	Anticorps monocaténaire bispécifique pscaxcd3 (cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 ou fapalpha xcd3), spécifique d'espèces croisées
AU2012245116A1 (en)	2011-04-20	2013-11-07	Genmab A/S	Bispecific antibodies against HER2 and CD3
SG11201509361TA (en)	2013-05-28	2015-12-30	Numab Ag	Novel antibodies
IL243311B (en)	2013-06-26	2022-07-01	Numab Therapeutics AG	New frameworks for antibodies
JP2016538275A (ja)	2013-11-04	2016-12-08	グレンマークファーマシューティカルズ，エセ．アー．	Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
CN106459201A (zh) *	2014-05-28	2017-02-22	豪夫迈·罗氏有限公司	结合人和食蟹猴CD3ε的抗体
CA2955947A1 (fr)	2014-07-25	2016-01-28	Cytomx Therapeutics, Inc.	Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispecifiques, anticorps anti-cd3 activables multispecifiques et procedes d'utilisation de ces anticorps
EP2982693A1 (fr) *	2014-08-07	2016-02-10	Affimed Therapeutics AG	Domaine de liaison CD3
MA40894A (fr) *	2014-11-04	2017-09-12	Glenmark Pharmaceuticals Sa	Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
WO2016184570A1 (fr) *	2015-05-18	2016-11-24	Numab Ag	Nouvelles méthodes de traitement sur la base de molécules multifonctionnelles
IL293435B1 (en)	2015-06-15	2026-04-01	Numab Therapeutics AG	Heterodimeric multispecific antibody format
JOP20160154B1 (ar) *	2015-07-31	2021-08-17	Regeneron Pharma	أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
SG11201911527QA (en) *	2017-06-05	2020-01-30	Numab Therapeutics AG	Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
EP3634998B8 (fr) *	2017-06-05	2025-04-09	Numab Therapeutics AG	Anticorps anti cd3 epsilon
EP3816185A1 (fr) *	2019-11-04	2021-05-05	Numab Therapeutics AG	Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
EP3915580A1 (fr) *	2020-05-29	2021-12-01	Numab Therapeutics AG	Anticorps multi-spécifique
KR20230018397A (ko) *	2020-05-29	2023-02-07	누맙 세러퓨틱스 아게	다중 특이적 항체

2018
- 2018-06-04 EP EP18729644.7A patent/EP3634998B8/fr active Active
- 2018-06-04 EP EP25159929.6A patent/EP4541819A3/fr active Pending
- 2018-06-04 US US16/619,121 patent/US11319371B2/en active Active
- 2018-06-04 ES ES18729644T patent/ES3015105T3/es active Active
- 2018-06-04 CN CN201880036701.7A patent/CN110691789A/zh active Pending
- 2018-06-04 AU AU2018280681A patent/AU2018280681B2/en active Active
- 2018-06-04 IL IL271128A patent/IL271128B2/en unknown
- 2018-06-04 MA MA049250A patent/MA49250A/fr unknown
- 2018-06-04 JP JP2019566606A patent/JP7247110B2/ja active Active
- 2018-06-04 KR KR1020197035542A patent/KR102651965B1/ko active Active
- 2018-06-04 CA CA3064163A patent/CA3064163A1/fr active Pending
2022
- 2022-04-22 US US17/727,449 patent/US20220403028A1/en not_active Abandoned
2025
- 2025-04-16 AU AU2025202700A patent/AU2025202700A1/en active Pending

Also Published As

Publication number	Publication date
CA3064163A1 (fr)	2018-12-13
KR20200013233A (ko)	2020-02-06
AU2018280681B2 (en)	2025-01-23
EP4541819A2 (fr)	2025-04-23
EP4541819A3 (fr)	2025-07-09
IL271128A (en)	2020-01-30
KR102651965B1 (ko)	2024-03-28
AU2018280681A1 (en)	2019-12-05
JP2020522260A (ja)	2020-07-30
EP3634998B1 (fr)	2025-02-26
US11319371B2 (en)	2022-05-03
EP3634998C0 (fr)	2025-02-26
US20200115449A1 (en)	2020-04-16
US20220403028A1 (en)	2022-12-22
AU2025202700A1 (en)	2025-05-08
IL271128B2 (en)	2024-10-01
ES3015105T3 (en)	2025-04-29
CN110691789A (zh)	2020-01-14
EP3634998B8 (fr)	2025-04-09
IL271128B1 (en)	2024-06-01
EP3634998A1 (fr)	2020-04-15
JP7247110B2 (ja)	2023-03-28

Publication	Publication Date	Title
FR24C1056I2 (fr)	2025-10-17	Nouveaux anticorps anti-pd-l1
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
MA52742A (fr)	2021-04-14	Anticorps bispécifiques dll3-cd3
MA52366A (fr)	2021-03-03	Anticorps anti-tl1a optimisés
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
EP3684806A4 (fr)	2021-09-22	Nouveaux anticorps anti-cd3epsilon
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
EP3498840A4 (fr)	2020-05-06	Anticorps anti-lag-3
EP3883970A4 (fr)	2022-03-30	Anticorps anti-b7-h3
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
EP3334763A4 (fr)	2019-04-03	Nouveaux anticorps anti-pd-1
EP3307777A4 (fr)	2019-02-13	Nouveaux anticorps anti-pd-l1
EP3507307A4 (fr)	2020-04-22	Anticorps bispécifiques
MA50352A (fr)	2020-08-19	Anticorps multispécifiques
EP3334757A4 (fr)	2019-04-03	Anticorps anti-tigit
DK3504241T3 (da)	2024-08-19	Anti-cd3-antistofformuleringer
EP3297671A4 (fr)	2019-02-06	Anticorps anti-ror1
MA49250A (fr)	2021-04-14	Nouveaux anticorps anti-cd3
EP3596126A4 (fr)	2021-03-03	Nouveaux anticorps anti-trkb
EP3492591A4 (fr)	2020-04-01	Anticorps anti-b7-h4
EP3526247A4 (fr)	2021-04-14	Anticorps anti-il1-rap
EP3617231A4 (fr)	2021-04-07	Anticorps anti-gpc-1
EP3484919A4 (fr)	2020-03-04	Anticorps anti-bêta-amyloïde